AbbVie cuts 2025 profit forecast on acquisition expenses
(Reuters) – On Thursday, he cut its 2025-adjusted profit forecast, as the drug expects to purchase $ 248 million in connection with research and development costs.
The company is concentrated on the expansion of its pipeline, as its blockbuster arthritis medicine, Humira lost the patent protection in 2023.
For this purpose, the company bought neuroscience drug developers, CEREVEL THERAPEutics, Importer of Cream Developers and Alzheimer Therapy Programming Aliada through $ 20 billion transactions.
Nearby. April 4, at 4:00. 01: 37 in EDT
ABBVIE expects an annual profit for each share of $ 11.99 to $ 12.19 compared to $ 12.12 to $ 12.32.
On average, analysts expected that the shares of the year amounted to $ 12.30, according to LSEG.
The company also expects the first quarterly adjusted profit to $ 2.34 to $ 2.38 per share compared to $ 2.51 per share for Wall Street.
On April 25, it is planned to report earnings in the first quarter.
(Puyan Singh reports in Bengalur; Editing Shreya Biswas)
English